Peter Donndorf

Dr. Peter Donndorf


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDPeter Donndorf
Peter Donndorf
GKGuenther Kundt
Guenther Kundt
AKAlexander Kaminski
Alexander Kaminski
CYCan Yerebakan
Can Yerebakan
ALAndreas Liebold
Andreas Liebold
AGAenne Glass
Aenne Glass

2 July 2012 in Trials
Verified
Journal Article
Open access
PDF file
PDPeter Donndorf
Peter Donndorf
AKAlexander Kaminski
Alexander Kaminski
GTGudrun Tiedemann
Gudrun Tiedemann
GKGuenther Kundt
Guenther Kundt
Gustav SteinhoffGustav Steinhoff
Gustav Steinhoff
For the last decade continuous efforts have been made to translate regenerative cell therapy protocols in the cardiovascular field from ‘bench to bedside’. Successful clinical introduction, supporting safety, and feasibility of this new therapeutic approach, led to the initiation of the German, Phase III, multicenter trial - termed the PERFECT trial (ClinicalTrials.gov Identifier: NCT00950274), in order to evaluate the efficacy of surgical cardiac cell therapy on left ventricular function.

1 September 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDPeter Donndorf
Peter Donndorf
FKFranziska Kühn
Franziska Kühn
BVBrigitte Vollmar
Brigitte Vollmar
JRJan Rösner
Jan Rösner
ALAndreas Liebold
Andreas Liebold
AKAlexander Kaminski
Alexander Kaminski

1 March 2012 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
PDPeter Donndorf
Peter Donndorf
BSBodo-Eckehard Strauer
Bodo-Eckehard Strauer
GSGustav Steinhoff
Gustav Steinhoff
Presentation of the current status of cardiac stem cell therapy for the treatment of ischaemic heart failure by highlighting recent clinical results and introducing ongoing trials. Furthermore, necessary upcoming procedural adjustments are discussed. During the last decade, stem cell application in the setting of ischaemic heart failure has been evaluated in phase I and II clinical trials, proving safety and feasibility of this approach. Functional results gained so far indicate moderate benefits. However, conclusive evaluation of cell therapy will not be possible before completion of ongoing phase III multicentre trials. Moreover, questions regarding the optimal cell population for treatment in a chronic setting and the favourable time-point of cell delivery have not been ultimately answered. Cell therapy for the treatment of ischaemic heart failure needs to be evaluated separately from the setting of acute myocardial infarction. In parallel with upcoming clinical evaluation in large-scale trials, further optimization of the ‘cell product’ regarding the favourable cell type and periprocedural processing, as well as route and time-point of application, is mandatory.

1 January 2013
Verified
Journal Article
Closed access
PDPeter Donndorf
Peter Donndorf
BSBodo-Eckhard Strauer
Bodo-Eckhard Strauer
AHAxel Haverich
Axel Haverich
Gustav SteinhoffGustav Steinhoff
Gustav Steinhoff

5 November 2012
Verified
Book Chapter
Closed access
PDF file
PDPeter Donndorf
Peter Donndorf
GSGustav Steinhoff
Gustav Steinhoff